Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has provided an announcement.
Pharmaron Beijing Co., Ltd. has released its interim results estimate for 2025, indicating a mixed financial performance. While the company’s revenue and non-IFRS adjusted net profit have shown year-on-year growth, the net profit attributable to owners of the parent has decreased significantly. This suggests a complex financial landscape where operational growth is overshadowed by non-recurring financial challenges, impacting the company’s profitability and potentially affecting stakeholder confidence.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on providing comprehensive research and development services to pharmaceutical and biotech companies, with a market focus on enhancing drug discovery and development processes.
Average Trading Volume: 8,282,990
Technical Sentiment Signal: Buy
Current Market Cap: HK$48.65B
See more data about 3759 stock on TipRanks’ Stock Analysis page.